Phibro Animal Health Corporation (PAHC)
USD 17.25
(2.5%)
USD 17.25
(2.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 1.01 Billion USD | 4.07% |
| 2023 | 977.88 Million USD | 3.78% |
| 2022 | 942.3 Million USD | 13.07% |
| 2021 | 833.4 Million USD | 4.12% |
| 2020 | 800.4 Million USD | -3.33% |
| 2019 | 828 Million USD | 0.98% |
| 2018 | 820 Million USD | 7.29% |
| 2017 | 764.3 Million USD | 1.7% |
| 2016 | 751.5 Million USD | 0.39% |
| 2015 | 748.59 Million USD | 8.19% |
| 2014 | 691.9 Million USD | 5.93% |
| 2013 | 653.15 Million USD | -0.15% |
| 2012 | 654.1 Million USD | 5.78% |
| 2011 | 618.33 Million USD | 4.06% |
| 2010 | 594.2 Million USD | 10.63% |
| 2009 | 537.1 Million USD | 5.03% |
| 2008 | 511.4 Million USD | 12.89% |
| 2007 | 453 Million USD | 13.7% |
| 2006 | 398.4 Million USD | 9.33% |
| 2005 | 364.4 Million USD | 2.82% |
| 2004 | 354.4 Million USD | 4.91% |
| 2003 | 337.8 Million USD | 2.77% |
| 2002 | 328.7 Million USD | 2.82% |
| 2001 | 319.7 Million USD | -1.02% |
| 2000 | 323 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 263.22 Million USD | 5.31% |
| 2024 Q4 | 273.16 Million USD | 3.78% |
| 2024 Q2 | 249.94 Million USD | 8.06% |
| 2024 FY | 1.01 Billion USD | 4.07% |
| 2024 Q1 | 231.3 Million USD | -9.31% |
| 2023 Q2 | 244.64 Million USD | 5.21% |
| 2023 Q4 | 255.04 Million USD | 3.81% |
| 2023 Q3 | 245.7 Million USD | 0.43% |
| 2023 FY | 977.88 Million USD | 3.78% |
| 2023 Q1 | 232.52 Million USD | -8.92% |
| 2022 Q2 | 232.71 Million USD | 8.41% |
| 2022 FY | 942.3 Million USD | 13.07% |
| 2022 Q4 | 255.3 Million USD | 6.54% |
| 2022 Q3 | 239.61 Million USD | 2.97% |
| 2022 Q1 | 214.66 Million USD | -2.56% |
| 2021 Q3 | 211.72 Million USD | 2.71% |
| 2021 Q4 | 220.3 Million USD | 4.05% |
| 2021 Q2 | 206.14 Million USD | 5.61% |
| 2021 Q1 | 195.19 Million USD | 5.0% |
| 2021 FY | 833.4 Million USD | 4.12% |
| 2020 Q4 | 185.9 Million USD | -11.79% |
| 2020 FY | 800.4 Million USD | -3.33% |
| 2020 Q1 | 189.72 Million USD | -6.95% |
| 2020 Q2 | 214.01 Million USD | 12.8% |
| 2020 Q3 | 210.73 Million USD | -1.53% |
| 2019 FY | 828 Million USD | 0.98% |
| 2019 Q2 | 218.22 Million USD | 9.03% |
| 2019 Q3 | 205.73 Million USD | -5.72% |
| 2019 Q4 | 203.9 Million USD | -0.89% |
| 2019 Q1 | 200.15 Million USD | -5.5% |
| 2018 Q2 | 205.87 Million USD | 6.44% |
| 2018 Q1 | 193.41 Million USD | -0.71% |
| 2018 FY | 820 Million USD | 7.29% |
| 2018 Q4 | 211.8 Million USD | 1.38% |
| 2018 Q3 | 208.9 Million USD | 1.47% |
| 2017 Q3 | 189.86 Million USD | -0.91% |
| 2017 Q1 | 187.98 Million USD | -0.64% |
| 2017 FY | 764.3 Million USD | 1.7% |
| 2017 Q4 | 194.8 Million USD | 2.6% |
| 2017 Q2 | 191.59 Million USD | 1.92% |
| 2016 FY | 751.5 Million USD | 0.39% |
| 2016 Q4 | 189.2 Million USD | 3.13% |
| 2016 Q3 | 183.46 Million USD | -4.33% |
| 2016 Q2 | 191.77 Million USD | 2.49% |
| 2016 Q1 | 187.12 Million USD | 1.17% |
| 2015 Q3 | 187.49 Million USD | -0.63% |
| 2015 FY | 748.59 Million USD | 8.19% |
| 2015 Q2 | 188.68 Million USD | 0.66% |
| 2015 Q4 | 184.95 Million USD | -1.36% |
| 2015 Q1 | 187.45 Million USD | 2.05% |
| 2014 Q2 | 172.74 Million USD | 6.48% |
| 2014 Q4 | 183.7 Million USD | 6.02% |
| 2014 Q1 | 162.22 Million USD | -1.2% |
| 2014 Q3 | 173.26 Million USD | 0.3% |
| 2014 FY | 691.9 Million USD | 5.93% |
| 2013 Q3 | 162.68 Million USD | -0.9% |
| 2013 Q2 | 164.15 Million USD | 0.63% |
| 2013 Q4 | 164.2 Million USD | 0.93% |
| 2013 Q1 | 163.13 Million USD | 0.0% |
| 2013 FY | 653.15 Million USD | -0.15% |
| 2012 FY | 654.1 Million USD | 5.78% |
| 2011 FY | 618.33 Million USD | 4.06% |
| 2010 Q2 | 151.8 Million USD | 11.37% |
| 2010 Q1 | 136.3 Million USD | -2.01% |
| 2010 FY | 594.2 Million USD | 10.63% |
| 2009 Q4 | 139.1 Million USD | 7.83% |
| 2009 Q3 | 129 Million USD | 1.02% |
| 2009 Q2 | 127.7 Million USD | -6.24% |
| 2009 FY | 537.1 Million USD | 5.03% |
| 2009 Q1 | 136.2 Million USD | -4.95% |
| 2008 Q4 | 143.3 Million USD | 8.23% |
| 2008 Q2 | 123.2 Million USD | 9.41% |
| 2008 Q1 | 112.6 Million USD | -8.31% |
| 2008 FY | 511.4 Million USD | 12.89% |
| 2008 Q3 | 132.4 Million USD | 7.47% |
| 2007 FY | 453 Million USD | 13.7% |
| 2007 Q4 | 122.8 Million USD | 13.28% |
| 2007 Q2 | 117 Million USD | 11.64% |
| 2007 Q1 | 104.8 Million USD | -0.38% |
| 2007 Q3 | 108.4 Million USD | -7.35% |
| 2006 Q2 | 99.7 Million USD | 7.67% |
| 2006 Q3 | 100.9 Million USD | 1.2% |
| 2006 Q4 | 105.2 Million USD | 4.26% |
| 2006 FY | 398.4 Million USD | 9.33% |
| 2006 Q1 | 92.6 Million USD | -2.73% |
| 2005 Q2 | 92 Million USD | 5.87% |
| 2005 FY | 364.4 Million USD | 2.82% |
| 2005 Q4 | 95.2 Million USD | 5.43% |
| 2005 Q1 | 86.9 Million USD | -6.36% |
| 2005 Q3 | 90.3 Million USD | -1.85% |
| 2004 Q3 | 86 Million USD | -5.18% |
| 2004 FY | 354.4 Million USD | 4.91% |
| 2004 Q1 | 85 Million USD | 19.38% |
| 2004 Q2 | 90.7 Million USD | 6.71% |
| 2004 Q4 | 92.8 Million USD | 7.91% |
| 2003 Q1 | 86.3 Million USD | 0.0% |
| 2003 Q3 | 90.2 Million USD | 0.11% |
| 2003 Q4 | 71.2 Million USD | -21.06% |
| 2003 FY | 337.8 Million USD | 2.77% |
| 2003 Q2 | 90.1 Million USD | 4.4% |
| 2002 FY | 328.7 Million USD | 2.82% |
| 2001 FY | 319.7 Million USD | -1.02% |
| 2000 FY | 323 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -79.559% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -52670.577% |
| Embecta Corp. | 1.12 Billion USD | 9.201% |
| Pacira BioSciences, Inc. | 674.97 Million USD | -50.772% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -4123.999% |
| SCYNEXIS, Inc. | 140.14 Million USD | -626.182% |
| Journey Medical Corporation | 79.18 Million USD | -1185.257% |
| Safety Shot Inc | 202.67 Thousand USD | -502035.985% |
| Alpha Teknova, Inc. | 36.68 Million USD | -2674.177% |
| Bright Green Corporation | 401.49 Thousand USD | -253374.922% |
| Procaps Group, S.A. | 409.92 Million USD | -148.263% |
| Alvotech | 91.43 Million USD | -1013.02% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -109.048% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1911.899% |
| Cosmos Health Inc. | 53.37 Million USD | -1806.592% |
| Dynavax Technologies Corporation | 232.28 Million USD | -338.118% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -774.791% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -119.153% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -4123.999% |
| Theratechnologies Inc. | 81.76 Million USD | -1144.654% |
| Harrow Health, Inc. | 130.19 Million USD | -681.67% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -7891.197% |
| Biofrontera Inc. | 34.07 Million USD | -2886.936% |
| DURECT Corporation | 8.54 Million USD | -11805.463% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -67.513% |
| Cronos Group Inc. | 88.84 Million USD | -1045.507% |
| OptiNose, Inc. | 70.98 Million USD | -1333.613% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -129.862% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -15524.934% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -134.954% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -8208.567% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -2472.982% |
| Radius Health, Inc. | 2.88 Billion USD | 64.691% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -3049.857% |
| ProPhase Labs, Inc. | 44.38 Million USD | -2192.896% |
| Procaps Group S.A. | 409.92 Million USD | -148.263% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -78062.75% |
| Viatris Inc. | 15.42 Billion USD | 93.403% |
| Rockwell Medical, Inc. | 83.61 Million USD | -1117.145% |
| Aytu BioPharma, Inc. | 81 Million USD | -1156.363% |
| SIGA Technologies, Inc. | 139.91 Million USD | -627.344% |
| Tilray Brands, Inc. | 788.94 Million USD | -28.993% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -693.444% |
| Shineco, Inc. | 9.8 Million USD | -10282.513% |
| PetIQ, Inc. | 1.1 Billion USD | 7.649% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -8480558.333% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 46.072% |
| Alimera Sciences, Inc. | 80.75 Million USD | -1160.221% |
| Silver Spike Investment Corp. | 11.72 Million USD | -8581.688% |
| Assertio Holdings, Inc. | 152.06 Million USD | -569.222% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -17378.722% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -5743.021% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -94444.247% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -3539.377% |
| Hempacco Co., Inc. | 4.04 Million USD | -25054.976% |
| Talphera, Inc. | 651 Thousand USD | -156225.499% |
| Alvotech | 91.43 Million USD | -1013.02% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -221.43% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 21.501% |
| Currenc Group, Inc. | 53.25 Million USD | -1810.942% |
| Kamada Ltd. | 144.75 Million USD | -603.017% |
| Indivior PLC | 1.09 Billion USD | 6.891% |
| Evoke Pharma, Inc. | 5.18 Million USD | -19543.924% |
| Flora Growth Corp. | 76.07 Million USD | -1237.802% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -94444.247% |
| Evolus, Inc. | 202.08 Million USD | -403.59% |
| HUTCHMED (China) Limited | 837.99 Million USD | -21.442% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -57.928% |
| Akanda Corp. | 2.16 Million USD | -47013.634% |